Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 3, 2013, Pages 348-355

  Mahler, Donald A ^a,b   Buhl, Roland ^c   Lawrence, David ^d   McBryan, Danny ^e  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Dyspnoea; Efficacy; Indacaterol; Safety; Tiotropium

Indexed keywords

INDACATEROL; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MODIFIEND MEDICAL RESEARCH COUNCIL SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; RHINOPHARYNGITIS; RISK REDUCTION; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; PATIENT ACUITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES;

EID: 84875954617     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.02.006     Document Type: Article

References (24)

1. Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated December 2011. [accessed 17.01.12]. http://www.goldcopd.org/.
2. Statement of a Medical Research Council Committee, Fletcher C.M. Standardized questionaires on respiratory symptoms. Br Med J 1960, 2:1665.
3. Mahler D.A., Rosiello R.A., Harver A., Lentine T., McGovern J.F., Daubenspeck J.A. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis 1987, 135:1229-1233.
4. Mahler D.A., Wells C.K. Evaluation of clinical methods for rating dyspnea. Chest 1988, 93:580-586.
5. Bestall J.C., Paul E.A., Garrod R., Garnham R., Jones P.W., Wedzicha J.A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999, 54:581-586.
6. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002, 121:1434-1440.
7. Jones P.W., Harding G., Berry P., Wiklund I., Chen W.H., Kline L.N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34:648-654.
8. Buhl R., Dunn L.J., Disdier C., Lassen C., Amos C., Henley M., et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011, 38:797-803.
9. Dahl R., Chung K.F., Buhl R., Magnussen H., Nonikov V., Jack D., et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479.
10. Donohue J.F., Fogarty C., Lotvall J., Mahler D.A., Worth H., Yorgancioglu A., et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162.
11. Kornmann O., Dahl R., Centanni S., Dogra A., Owen R., Lassen C., et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011, 37:273-279.
12. Mahler D.A., Weinberg D.H., Wells C.K., Feinstein A.R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758.
13. Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
14. Cazzola M., MacNee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
15. Mahler D.A., Witek T.J. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005, 2:99-103.
16. Witek T.J., Mahler D.A. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003, 56:248-255.
17. Witek T.J., Mahler D.A. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003, 21:267-272.
18. Jones P.W. St. George's Respiratory Questionnaire: MCID. COPD 2005, 2:75-79.
19. Evans R.A., Singh S.J., Collier R., Williams J.E., Morgan M.D. Pulmonary rehabilitation is successful for COPD irrespective of MRC dyspnoea grade. Respir Med 2009, 103:1070-1075.
20. Wedzicha J.A., Bestall J.C., Garrod R., Garnham R., Paul E.A., Jones P.W. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1998, 12:363-369.
21. Mahler D.A., Waterman L.A., Ward J., McCusker C., ZuWallack R., Baird J.C. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest 2007, 132:1283-1290.
22. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., Kesten S. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2006, 61:91.
23. Korn S., Kerwin E., Atis S., Amos C., Owen R., Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011, 105:719-726.
24. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002, 19:209-216.